Medtronic (MDT) is preparing to spin off its Diabetes division, MiniMed into a standalone company with completion expected by mid‑ to late 2026, structured as an IPO followed by a split-off to shareholders, the company announced on May 21, 2025. The company’s presentation on the transaction can be found here. Led by Que Dallara, the division encompasses approximately 8,000 employees and generated around $2.8 billion in FY 2025 revenue, marking approximately 11% year-over-year growth.
The rationale: the diabetes unit’s direct-to-consumer model and product focus differ fundamentally from Medtronic’s hospital-facing offerings. Separating the businesses allows sharper strategy, improved margins, and value unlocking for shareholders.
MiniMed is Reborn
Though the initial announcement did not name the new company, Medtronic followed up with a few weeks later, naming the new company MiniMed. MiniMed was the name of a precursor diabetes focused company that Medtronic acquired in 2001, originally founded in 1983.
“Our journey began in 1983, when visionary entrepreneur Alfred E. Mann founded MiniMed and revolutionized diabetes care with many first-of-its-kind innovations that pushed the boundaries of care and helped simplify life with diabetes for countless people around the world,” said Que Dallara, current EVP and President of Medtronic Diabetes and Chief Executive Officer designate of MiniMed. “We’re thrilled to honor this rich 40-year legacy with a name that carries deep meaning and trust. As we step forward into this new and exciting chapter, we’ll focus relentlessly on fulfilling our Mission to make diabetes more predictable so everyone can embrace life to the fullest.”
A New CFO For MiniMed
On July 8, 2025, Medtronic announced it had hired Chad Spooner to be CFO of MiniMed.
Chad brings over 25 years of financial leadership experience across healthcare, consumer, and industrial sectors. Most recently, he served as CFO at BIC (BB:PA), a publicly traded global consumer goods leader, where he played a pivotal role in the successful execution of the company’s transformation to drive innovation, sustainable growth, operational efficiency, and shareholder value. He started his career at General Electric, where he spent a decade in management positions of increasing responsibility in corporate audit and financial planning, as well as in a senior finance role in GE Energy. Chad then assumed CFO roles at Raffaela Apparel Group (a Cerberus Capital Management portfolio company) and Slingshot Health, and held senior operational finance roles at Tenex Capital Management, a middle-market private equity firm he co-founded with over $1 billion in investments. He holds a BS in Mechanical Engineering from the Massachusetts Institute of Technology (MIT) and serves on the board of directors at Stamford Hospital.
Spin-Off Snapshot: Quick Facts
| Feature | Details |
|---|---|
| Spinoff Name | MiniMed |
| Leadership | CEO: Que Dallara |
| Workforce | ~8,000 employees |
| FY 2025 Revenue | ~$2.8B (10–11% YoY growth) |
| Profit Contribution | ~4% of Medtronic segment profit |
| Separation Timeline | IPO + split-off, target late 2026 |
| Expected Benefits For Medtronic | ~50 bps gross margin, ~100 bps operating margin, EPS accretion |
| Strategic Rationale | Focused businesses, margin clarity, responsive strategy |
Why Now? GLP‑1s and Market Disruption
The spin-off comes amid a shifting treatment landscape where GLP‑1 receptor agonists—including Ozempic, Wegovy, and Mounjaro—have redefined diabetes care. These drugs offer powerful glucose control and weight loss, reducing the need for insulin in many Type 2 patients and potentially dampening demand for delivery devices.
Medtronic leadership maintains that the insulin-dependent Type 1 diabetes market remains robust, and AID systems are still critical. Nevertheless, the business risks fragmentation as GLP‑1 therapies blur the traditional device-driven management model.
By spinning off the Diabetes unit, Medtronic allows MiniMed to directly pursue digital strategy, innovation, and direct patient engagement—without being weighed down by legacy business models.
Financial & Strategic Highlights
2025 Diabetes Revenue: ~$2.8B, marking consistent double-digit growth
Medtronic Core: expected margin expansion and EPS uplift post-spin
MiniMed Path: Ability to channel funds into Smart Pens, digital tools, and patient services
Investor Impacts: Medtronic shareholders retain exposure to both growth and margin advantages
Structural & Market Considerations
Spin Model: IPO followed by split-off, framed to be tax-efficient to shareholders
Regulatory Approval: Pending, along with alignment from institutional investors
Market Timing: Is the market strong enough in late 2026 for a dual offering? That remains a key risk
Programmatic Pressures: GLP‑1 disruption, competition from Dexcom and Abbott, and new device entrants require nimble strategy
Why This Spin Makes Sense
Medtronic’s spin mirrors broader healthcare trends where specialization and capital efficiency drive performance:
- Investor Clarity – Pure plays trade more attractively
- Strategic Freedom – MiniMed can innovate faster in patient-focused therapies
- Margin Improvement – Simplified cost structure supports healthier Pro Forma margins
- GLP‑1 Evolution – Separating allows both entities to adapt to evolving patient care paradigms
What Does the MiniMed Spinoff Mean for Medtronic?
Following the diabetes spin-off, Medtronic’s remaining portfolio will be more streamlined and focused on its higher-growth, higher-margin businesses, with projected annual revenue of approximately $28 billion post-separation. Key performance drivers include its cardiac rhythm and cardiovascular units, the Hugo robotic-assisted surgery platform, and expanding neuromodulation and pulsed field ablation (PFA) offerings. The company has been investing heavily in R&D and international market access to drive adoption across these advanced therapies. With the diabetes unit no longer weighing on margins, Medtronic anticipates gross margin expansion of around 50 basis points and operating margin improvement of 100 basis points, resulting in near-term earnings per share accretion. The leaner structure should also support more disciplined capital allocation and improved long-term returns for shareholders.
Absolutely — here is the fully revised Medtronic spinoff history section, now integrated with accurate information about Physio-Control and no placeholder artifacts. It is styled and formatted for publication on StockSpinoffs.com:
Medtronic’s Spinoff Track Record: Lessons from the Past
Though Medtronic is best known for cardiovascular and surgical innovations, the company has not shied away from structural shakeups when the strategic need arises. The planned spin of its diabetes business may be its highest-profile divestiture to date, but it’s far from Medtronic’s first attempt to carve out value.
The Spin-off That Wasn’t: Physio-Control
Back in 2006, Medtronic announced its intention to spin off Physio-Control, its external defibrillator and emergency response unit headquartered in Redmond, Washington. The business had once been a crown jewel, acquired in 1998 for $538 million and generating nearly $450 million in annual revenue by the mid-2000s.
But the spin was derailed before it ever reached the starting line. The U.S. FDA raised serious concerns about Physio-Control’s quality control systems, and in 2008, the business entered into a consent decree that limited its ability to distribute products until compliance issues were resolved. What was meant to be a clean separation turned into a long period of remediation.
In 2011, Medtronic revisited this spinoff, but ultimately, rather than pursue a spin in the public markets, Medtronic sold the business to Bain Capital in late 2011 for $487 million in cash. Physio-Control became an independent company—but only temporarily. In 2016, Stryker acquired it for $1.28 billion, absorbing it into its Emergency Care division.
The trajectory of Physio-Control offers a cautionary tale: even when a business seems ready for a standalone future, operational complexity and regulatory risk can force a change of plans.
Covidien: The Reverse-Carveback
Medtronic’s 2014 acquisition of Covidien marked a high-profile reversal of the typical spinoff narrative. Covidien itself had been a spinoff from Tyco International in 2007, intended to unlock the value of its surgical supply and device business. In a twist, Medtronic turned around and acquired Covidien just seven years later for $42.9 billion in cash and stock, gaining tax efficiencies and expanding its international footprint.
This kind of strategic reabsorption reflects Medtronic’s flexible thinking on corporate structure: sometimes spinning, sometimes acquiring—but always looking to align structure with opportunity.
Medtronic’s strategic divestiture of its Diabetes division represents a compelling response to structural market shifts—from device-focused care to drug-driven metabolism management. While Medtronic powers ahead in heart surgery, robotics, and ablation, MiniMed gets the flexibility to compete directly in a rapidly evolving diabetes ecosystem.